 TEL AVIV, Israel, Feb. 08, 2021 GLOBE NEWSWIRE -- InspireMD, Inc. InspireMD NYSE:NSPR, a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately 20.7 million, which includes the full exercise of the underwriters over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by InspireMD. 